Project Grant HT9425261E333
Award Date 9/1/26
Completion Date 8/31/30
Dollars Obligated $2.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Switzerland
Similar Awards
- The Defense Health Agency awarded $1.4 million to Fondazione Per L'istituto Oncologico DI Ricerca (Ior) on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to identify and target non-coding mechanisms of follicular lymphoma transformation. The recipient, based in Switzerland, will conduct basic and applied biomedical research aimed at advancing medical solutions relevant to Service Members and the American public. The award runs through August 31,...
- The U.S. Defense Health Agency awarded a $989,167 Project Grant to the University of Bern in Switzerland under the Military Medical Research and Development program (CFDA 12.420). The grant, effective from February 15, 2024 to February 14, 2027, supports research to define the role of the SWI/SNF chromatin remodeling complex in advanced metastatic castration-resistant prostate cancer (mCRPC) therapy resistance. Through this grant, the University of Bern will conduct basic, translational, and...
- The Defense Health Agency awarded The Rockefeller University $1.649998 million on August 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct therapeutic targeting of a commonly inherited breast cancer metastasis driver gene. Work performance is located in New York, NY with a period of performance through July 31, 2029. The Military Medical Research and Development program funds basic, applied, and advanced biomedical research to transform health care for...
- The Defense Health Agency awarded Emory University $2.099 million on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate the dark proteome of advanced prostate cancer. The project runs through August 31, 2029, with place of performance in Atlanta, Georgia. The award supports basic and applied biomedical research aimed at transforming health care for Service Members and the American public through innovative research and investigation of...
- The Defense Health Agency awarded Dana-Farber Cancer Institute, Inc. $2 million under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2026, to support the Prostate Cancer Clinical Trials Consortium. The award funds clinical trial coordination and research activities from September 30, 2026, through September 29, 2030, at Dana-Farber's Boston, Massachusetts location. The Military Medical Research and Development program supports basic, applied, and advanced...
- The Defense Health Agency awarded the University of Wisconsin System $2 million on September 30, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support the Prostate Cancer Clinical Trials Consortium at the University of Wisconsin Carbone Cancer Center. The award, classified as a Project Grant, funds clinical trials research and related activities through September 29, 2030, with performance in Madison, Wisconsin. The Military Medical Research and Development...
- The Defense Health Agency awarded University of California, San Diego $1.65 million on May 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct research targeting oncoembryonic antigens to overcome therapy resistance in patients with triple-negative breast cancer. The award is a Project Grant with a period of performance from May 1, 2026, through April 30, 2029. Work is performed in La Jolla, California. The Military Medical Research and Development...
- The Defense Health Agency awarded New York University School of Medicine $750,962 on June 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate neoadjuvant checkpoint and IL-6 blockade mechanisms of benefit and toxicity. The award supports basic and applied biomedical research with a period of performance through June 14, 2029. Work is performed in New York, New York. The Military Medical Research and Development program funds research to transform...
- The Defense Health Agency awarded University of Massachusetts Medical School $1.699 million on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to determine the contribution of interferon gamma signaling to neuroendocrine prostate cancer progression and immunotherapy resistance. The three-year project runs through June 30, 2029, with work performed in Worcester, Massachusetts. The award supports basic biomedical research to investigate medical solutions...
- The Defense Health Agency awarded The Regents of the University of California, San Francisco $1.199424 million on September 30, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support research targeting the glucocorticoid receptor to enhance immunotherapy response in metastatic castration-resistant prostate cancer. The award runs through September 29, 2029, with place of performance in San Francisco, California. The Military Medical Research and Development...